Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

1) What happened: Representative Quigley (D-IL) introduced HR8205 on April 6, 2026, referred to the House Energy and Commerce Committee. The bill would extend the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) through FY2031, adding new FDA oversight provisions for requesting interim clinical trial data and clarifying that phase 2/3 combined trials count as phase 3 for program eligibility. It also includes a non-binding Sense of Congress supporting direct appropriation for ALS programs. 2) The money trail: This is a pure authorization bill with zero appropriated funds. The bill merely extends the sunset of existing programs from 2026 to 2031 and adds procedural tweaks. The Sense of Congress section explicitly acknowledges that funding requires separate appropriations. No dollar amounts appear anywhere in the bill text. For retail investors, this means the bill has no immediate ability to fund research grants, contracts, or drug purchases. 3) Structural winners and losers: The only pure-play ALS biotech exposure is Cytokinetics, which has ALS-related programs but whose primary pipeline is in cardiac muscle biology. Other companies with ALS exposure include Biogen ($BIIB, FDA-approved Qalsody for SOD1-ALS) and AbbVie ($ABBV, no ALS therapy). The structural linkage to is weak—ALS is not the company's primary revenue driver, and the bill provides no funding. 4) Real market data analysis: is at $63.84, down 2.27% over 7 days and 3.14% over 30 days. The introduction of HR8205 on April 6 shows no discernible price effect ( closed at $66.71 on April 17, well after introduction, and has since declined). $BIIB at $191.46 shows a 4.43% 30-day gain driven by broader factors, not ALS legislation. $ABBV at $213.01 has a 7.2% weekly gain unrelated to this bill. 5) Timeline: This bill has no committee markup scheduled, no companion Senate bill (no related bills listed), and 35 cosponsors (all House). For context, similar ALS reauthorization bills in past congresses have taken 6–18 months to pass. The 119th Congress has 1.5 years remaining. Passage probability is moderate but distant.